| Project/Area Number |
26461436
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
横田 明日美 京都大学, 医学研究科, 研究員 (00571556)
|
|---|
| Research Collaborator |
SHIMAZAKI CHIHIRO 地域医療機能推進機構京都鞍馬口医療センター, 院長
TAKADA TESTUYA 京都薬科大学, 薬学部, 大学院生
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 多発性骨髄腫 / がん幹細胞 / 骨髄微小環境 / 低酸素環境 / TGF-β / C7orf24 |
|---|
| Outline of Final Research Achievements |
The prognosis of patients with multiple myeloma (MM) has been improved by the emergence of new molecular targeting agents including proteasome inhibitors and immunomodulating agents. Nevertheless, MM remains incurable at present because it is likely that MM stem cells are resistant to these targeting agents. Thus, it is important to further investigate the biology of MM stem cells to cure the MM patients. We have established the hypoxia-adapted MM cells (MM-HA) that can survive under hypoxic conditions (O2 1%) for more than six months and these MM-HA cells have cancer stem cell-like characters. In this project, we clarified further characters of HA-MM cells. HA-MM cells have significantly higher plating efficiencies in a clonogenic replating assay. Moreover, the inhibition of TGF-β/Smad signaling reduced plating efficiencies, suggesting that TGF-β/Smad signal could be a novel target against MM-stem cells.
|
